Skip to content
Triangle logo TriangleGet started
← Soft Tissue Sarcoma

NCT01079832 · STUDY IN CONTEXT

Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.

Intent to treat

→

secondary · POSTED

Median disease free survival

Intent to treat

→

secondary · POSTED

Length of time patients survived at study end.

Intent to treat

→

secondary · POSTED

Quality of Life

Participant surveys were unreliably returned to investigators, making this analysis not meaningful.

→

secondary · POSTED

Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).

Intent to treat

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

Unnamed quality-of-life measure · Quality of Life

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-soft-tissue-sarcoma
nct id
NCT01079832
qol key
qol-0003
source section id
NCT01079832-om-0003
source outcome index
3
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Quality of Life
measure definition
Source null
time frame
After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Participant surveys were unreliably returned to investigators, making this analysis not meaningful.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-soft-tissue-sarcoma
nct id
NCT01079832
trial label
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
5
harms Count
1
qol Count
1
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0000
    source section id
    NCT01079832-om-0000
    source outcome index
    0
    endpoint
    Acute Toxicity Rate
    endpoint definition
    The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.
    time origin
    at 6 months after treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Intent to treat
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0001
    source section id
    NCT01079832-om-0001
    source outcome index
    1
    endpoint
    Disease-free Survival
    endpoint definition
    Median disease free survival
    time origin
    completion of study at 24 months
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Intent to treat
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0002
    source section id
    NCT01079832-om-0002
    source outcome index
    2
    endpoint
    Median Overall Survival
    endpoint definition
    Length of time patients survived at study end.
    time origin
    24 months
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Intent to treat
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0003
    source section id
    NCT01079832-om-0003
    source outcome index
    3
    endpoint
    Quality of Life
    endpoint definition
    Quality of Life
    time origin
    After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Participant surveys were unreliably returned to investigators, making this analysis not meaningful.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0004
    source section id
    NCT01079832-om-0004
    source outcome index
    4
    endpoint
    Clinical Response Rate
    endpoint definition
    Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).
    time origin
    at 6 months from study entry
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Intent to treat
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Arm I: CyberKnife Radiosurgery
    regimen
    Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
    analyzed count
    50
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01079832-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Arm I: CyberKnife Radiosurgery
    regimen
    Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
    analyzed count
    50
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01079832-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Arm I: CyberKnife Radiosurgery
    regimen
    Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
    analyzed count
    50
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01079832-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Arm I: CyberKnife Radiosurgery
    regimen
    Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01079832-om-0003#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    outcome key
    om-0004
    arm key
    OG000
    arm label
    Arm I: CyberKnife Radiosurgery
    regimen
    Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
    analyzed count
    50
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01079832-om-0004#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    harm key
    EG000
    source section id
    NCT01079832-ae
    event group key
    EG000
    event group label
    Arm I: CyberKnife Radiosurgery
    serious affected
    3
    serious at risk
    50
    other affected
    34
    other at risk
    50
    frequency threshold
    5
    collection period
    Adverse events were collected while patients were receiving treatment and during 6 months of follow up.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-soft-tissue-sarcoma
    nct id
    NCT01079832
    qol key
    qol-0003
    source section id
    NCT01079832-om-0003
    source outcome index
    3
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Quality of Life
    measure definition
    Source null
    time frame
    After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    Participant surveys were unreliably returned to investigators, making this analysis not meaningful.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
setting source links

    Preserved source evidence · Not medical advice